Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Xencor, Inc. (NASDAQ:XNCR) have received a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $22.25.

Several analysts recently commented on the company. Wedbush reaffirmed an “outperform” rating and issued a $26.00 price objective on shares of Xencor in a report on Tuesday, September 2nd. Royal Bank Of Canada cut their price objective on Xencor from $32.00 to $15.00 and set an “outperform” rating for the company in a report on Thursday, August 21st. Wells Fargo & Company cut their price objective on Xencor from $33.00 to $27.00 and set an “overweight” rating for the company in a report on Thursday, August 7th. Finally, Bank of America lowered Xencor from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $23.00 to $12.00 in a report on Wednesday, September 3rd.

Institutional Trading of Xencor

Large investors have recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new stake in Xencor during the fourth quarter valued at about $34,000. State of Wyoming bought a new stake in Xencor during the first quarter valued at about $34,000. CWM LLC grew its holdings in Xencor by 195.5% during the first quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 2,231 shares during the period. Mackenzie Financial Corp bought a new stake in Xencor during the fourth quarter valued at about $101,000. Finally, AlphaQuest LLC bought a new stake in Xencor during the first quarter valued at about $56,000.

Xencor Price Performance

XNCR stock opened at $8.49 on Tuesday. Xencor has a 1-year low of $6.92 and a 1-year high of $27.24. The business has a fifty day moving average price of $8.33 and a 200-day moving average price of $9.28. The stock has a market capitalization of $605.53 million, a P/E ratio of -3.54 and a beta of 0.82.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.37. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%.The firm had revenue of $43.61 million during the quarter, compared to analysts’ expectations of $22.59 million. During the same quarter in the previous year, the business earned ($1.07) earnings per share. The company’s revenue was up 82.4% on a year-over-year basis. As a group, analysts anticipate that Xencor will post -3.68 earnings per share for the current year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.